Teacher Retirement System of Texas lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 11.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 115,392 shares of the biopharmaceutical company's stock after buying an additional 12,302 shares during the period. Teacher Retirement System of Texas' holdings in Royalty Pharma were worth $2,944,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Keene & Associates Inc. lifted its stake in Royalty Pharma by 1.9% during the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock valued at $495,000 after acquiring an additional 370 shares during the period. Blue Trust Inc. raised its holdings in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 376 shares during the last quarter. Sanctuary Advisors LLC lifted its position in Royalty Pharma by 0.9% during the fourth quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock valued at $1,068,000 after purchasing an additional 388 shares during the period. Arizona State Retirement System boosted its holdings in Royalty Pharma by 0.5% in the fourth quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company's stock worth $2,822,000 after purchasing an additional 537 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Royalty Pharma by 31.4% in the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 590 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.
Royalty Pharma Stock Performance
Shares of NASDAQ:RPRX traded down $0.28 during midday trading on Friday, hitting $31.37. The company had a trading volume of 4,077,104 shares, compared to its average volume of 3,103,202. The company has a market cap of $18.08 billion, a price-to-earnings ratio of 21.63, a PEG ratio of 2.31 and a beta of 0.47. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company has a fifty day moving average of $32.44 and a two-hundred day moving average of $28.85. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities research analysts expect that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.
Royalty Pharma Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were issued a dividend of $0.22 per share. The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.81%. This is an increase from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's payout ratio is currently 60.69%.
Analyst Ratings Changes
RPRX has been the topic of several research analyst reports. TD Cowen raised Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a report on Friday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Royalty Pharma presently has a consensus rating of "Buy" and an average price target of $41.60.
View Our Latest Research Report on RPRX
About Royalty Pharma
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Stories
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
